Home - Clinical Trials Arena
WEBAstraZeneca eyes up transition to eco-friendly inhaler propellant. Results from AstraZeneca’s completed clinical studies will be shared with regulatory authorities by the end of this year. More themes. Artificial Intelligence.
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEBAug 25, 2021 · Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said. Manasi Vaidya August 25, 2021. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is also a new drug class in HIV.
Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA
WEBJun 19, 2024 · Mounjaro ™ (tirzepatide) is a dual-targeted, injectable, sustained-release therapy indicated for the treatment of type 2 diabetes (T2D) in adults as an adjunct to diet and exercise.. Developed by Eli Lilly, a pharmaceutical company based in the US, Mounjaro is the first and only once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor ...
Phase 0 clinical trials: what you need to know
WEBJul 21, 2022 · Clinical Trials Arena breaks down the two most common types of Phase 0 trials, including window of opportunity trials in neuro-oncology. William Newton July 21, 2022. When the FDA introduced Phase 0 trials in 2006, the goal was to learn more about new drugs without exposing subjects to their full, potentially toxic, effects.
EMA enforces transparency with new clinical trial rules
WEBOct 10, 2023 · The European Medicines Agency (EMA) has revised its transparency rules on publishing information about clinical trials submitted through the Clinical Trials Information System (CTIS). EMA aims to expedite access to trial information to stakeholders including patients and healthcare professionals (HCPs). The revised rules will apply after their ...
Tizona begins Phase Ib expansion trial of advanced malignancy …
WEBOct 15, 2021 · Tizona Therapeutics has commenced the Phase Ib clinical trial of its lead experimental therapy, TTX-080, in patients with advanced refractory or resistant malignancies. TTX-080 is a new antibody that acts on human leukocyte antigen G (HLA-G), an immune checkpoint expressed across various kinds of tumours. The investigational therapy hinders HLA ...
A closer look at Regeneron and its efforts to provide Covid-19 …
WEBJun 19, 2020 · Having grown into one of the biggest companies in the biotech sphere since its inception in 1988, Regeneron is now working to develop a Covid-19 treatment. Regeneron is testing sarilumab – an existing rheumatoid arthritis drug – in Covid-19 patients (Credit: Regeneron/Sanofi) Like many firms in the pharmaceutical sector, Regeneron has ...
CanSino’s shot shows 96% efficacy against severe Covid-19 in trial
WEBDec 27, 2021 · CanSino Biologics (CanSinoBIO) has reported that its recombinant Covid-19 vaccine, Convidecia, demonstrated 96% efficacy in averting severe disease in Phase III clinical trial. The international, randomised, double-blind, multicentre and placebo-controlled trial enrolled 45,000 adult subjects aged 18 years and above in Argentina, Chile, Mexico ...
Axcella previews long Covid registrational trial plans in UK and US
WEBAug 2, 2022 · Axcella Therapeutics is in discussions with the UK Medicines and Healthcare products Regulatory Agency (MHRA) to run a registrational trial of AXA1125 in long Covid-19, CEO Bill Hinshaw says. The biotech plans to initiate regulatory conversations with the US Food and Drug Administration (FDA) in the “near term”, he tells Clinical Trials Arena.
Remdesivir for Potential Treatment of Covid-19 - Clinical Trials Arena
WEBMar 2, 2020 · Remdesivir is an investigational antiviral drug being developed by Gilead Sciences for the treatment of Covid-19, a coronavirus disease, and Ebola virus infection. The drug is currently not approved for any indication globally. The US Food and Drug Administration (FDA) reviewed the investigational new drug (IND) application filed by …
Skip to content